NLS Pharmaceutics AG
NASDAQ:NLSP
Cash Flow Statement
Cash Flow Statement
NLS Pharmaceutics AG
| Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||
| Net Income |
(5)
|
(3)
|
(3)
|
(6)
|
(12)
|
(16)
|
(17)
|
(15)
|
(12)
|
(7)
|
(2)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Non-Cash Items |
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
(2)
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
4
|
2
|
2
|
(4)
|
(3)
|
3
|
2
|
1
|
2
|
2
|
0
|
|
| Cash from Operating Activities |
(0)
N/A
|
(1)
-653%
|
(1)
+49%
|
(10)
-1 260%
|
(15)
-50%
|
(13)
+14%
|
(14)
-8%
|
(14)
+3%
|
(10)
+28%
|
(4)
+60%
|
(4)
-9%
|
|
| Investing Cash Flow | ||||||||||||
| Capital Expenditures |
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Cash from Investing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
-33%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
|
| Financing Cash Flow | ||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
19
|
22
|
7
|
17
|
13
|
0
|
1
|
5
|
|
| Net Issuance of Debt |
1
|
1
|
1
|
(1)
|
(2)
|
(0)
|
1
|
1
|
2
|
1
|
0
|
|
| Other |
(0)
|
(0)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Cash from Financing Activities |
0
N/A
|
0
-17%
|
1
+47%
|
17
+3 270%
|
20
+21%
|
7
-65%
|
17
+144%
|
14
-21%
|
2
-88%
|
3
+73%
|
5
+79%
|
|
| Change in Cash | ||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Net Change in Cash |
0
N/A
|
(1)
N/A
|
(0)
+88%
|
7
N/A
|
5
-23%
|
(6)
N/A
|
4
N/A
|
0
-91%
|
(8)
N/A
|
(1)
+86%
|
1
N/A
|
|
| Free Cash Flow | ||||||||||||
| Free Cash Flow |
(0)
N/A
|
(1)
-653%
|
(1)
+49%
|
(10)
-1 264%
|
(15)
-50%
|
(13)
+14%
|
(14)
-8%
|
(14)
+3%
|
(10)
+28%
|
(4)
+60%
|
(4)
-9%
|
|